[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hairy-cell-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":92,"states":97},"Hairy Cell Leukemia",13,10,[8,16,22,28,35,42,48,54,60,66,72,79,86],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04322383","Binimetinib for People With Relapsed\u002FRefractory BRAF Wild Type Hairy Cell Leukemia and Variant",[12],"Phase 2","RECRUITING","2026-08-26T02:17:33.807405Z","2026-07-24T01:27:14.929254Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06561360","A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)",[12],"2026-08-26T02:17:35.666428Z","2026-07-05T05:32:16.759375Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT00412594","Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia",[12],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:28.638791Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06965114","Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia",[32],"Phase 1\u002FPhase 2","2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.916844Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT04815356","Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed\u002FRefractory Hairy Cell Leukemia and Variant",[39],"Phase 1","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:27.133485Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06311227","Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:35:31.905233Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[39],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.925479Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04775745","Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.",[39],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.754680Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT02560883","Hairy Cell Leukemia Patient Data Registry",[],"2026-08-26T02:16:26.411851Z","2026-05-13T02:55:06.096502Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT01087333","Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment",[],"2026-08-26T02:16:51.982021Z","2026-05-13T02:55:06.067187Z",{"nct_id":73,"title":74,"phases":75,"status":76,"updated_at":77,"content_modified":78},"NCT07679919","BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies",[39],"NOT_YET_RECRUITING","2026-08-26T02:15:42.447052Z","2026-07-05T03:45:20.442522Z",{"nct_id":80,"title":81,"phases":82,"status":83,"updated_at":84,"content_modified":85},"NCT04324112","Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed\u002FRefractory HCL",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:21:18.692511Z","2026-05-05T02:43:29.644900Z",{"nct_id":87,"title":88,"phases":89,"status":83,"updated_at":90,"content_modified":91},"NCT05362773","A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies",[39],"2026-08-03T03:16:06.901903Z","2026-05-05T02:43:29.384678Z",[93],{"biomarker":94,"count":95,"slug":96},"BRAF Gene",3,"braf-gene",[98,102],{"state":99,"count":100,"slug":101},"Maryland",7,"maryland",{"state":103,"count":104,"slug":105},"Ohio",6,"ohio"]